Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal.

  • Read more about A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal.

Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

  • Read more about Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Asymmetry-defective oligodendrocyte progenitors are glioma precursors.

  • Read more about Asymmetry-defective oligodendrocyte progenitors are glioma precursors.

Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

  • Read more about Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Non-stem cell origin for oligodendroglioma.

  • Read more about Non-stem cell origin for oligodendroglioma.

The SPS affair: a complex tale of illicit proliferation.

  • Read more about The SPS affair: a complex tale of illicit proliferation.

JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.

  • Read more about JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.

Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

  • Read more about Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.

  • Read more about Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  • Read more about A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Pagination

  • Previous page ‹‹
  • Page 3
  • Next page ››
Subscribe to Cancer cell

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List